Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 8, 2026, concerns Xenetic Biosciences, Inc., a Nevada corporation headquartered in Framingham, Massachusetts. The report addresses corporate governance events regarding the company's 2025 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate meeting logistics and contains no financial performance data.
Material Changes and Events
- Meeting Adjournment: The 2025 Annual Meeting, originally scheduled for December 11, 2025, was adjourned to January 8, 2026, to solicit additional proxies and achieve a quorum.
- Failed Reconvening: On January 8, 2026, the meeting was reconvened but adjourned again without conducting any business due to a continued lack of a requisite quorum.
- Future Action: The Company intends to reconvene the Annual Meeting at a new, undetermined date and time, with advance notice to be provided to stockholders.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operations, or specific risk factors beyond the immediate inability to hold a stockholder meeting. The primary contingency is the uncertainty regarding the rescheduled date for the Annual Meeting.
Key Facts for Investor Verification
- Verify the date and time of the next reconvened Annual Meeting once announced.
- Confirm the current status of proxy solicitation efforts to ensure a quorum can be achieved.
- Review the agenda for the 2025 Annual Meeting to understand which corporate actions (e.g., director elections, executive compensation) are pending.
- Monitor subsequent filings for updates on the meeting schedule and any potential impact on corporate governance.